AU2011204370B2 - Hedgehog inhibitors - Google Patents

Hedgehog inhibitors Download PDF

Info

Publication number
AU2011204370B2
AU2011204370B2 AU2011204370A AU2011204370A AU2011204370B2 AU 2011204370 B2 AU2011204370 B2 AU 2011204370B2 AU 2011204370 A AU2011204370 A AU 2011204370A AU 2011204370 A AU2011204370 A AU 2011204370A AU 2011204370 B2 AU2011204370 B2 AU 2011204370B2
Authority
AU
Australia
Prior art keywords
alkyl
aryl
compound
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011204370A
Other languages
English (en)
Other versions
AU2011204370A1 (en
Inventor
Pierre-Yves Bounaud
Stephanie Hopkins
John May
Patrick O'connor
Anthony Pinkerton
William Ripka
Jean-Michel Vernier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selexagen Therapeutics Inc
Original Assignee
Selexagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selexagen Therapeutics Inc filed Critical Selexagen Therapeutics Inc
Publication of AU2011204370A1 publication Critical patent/AU2011204370A1/en
Application granted granted Critical
Publication of AU2011204370B2 publication Critical patent/AU2011204370B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2011204370A 2010-01-07 2011-01-06 Hedgehog inhibitors Ceased AU2011204370B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29312810P 2010-01-07 2010-01-07
US61/293,128 2010-01-07
PCT/US2011/020416 WO2011085128A1 (en) 2010-01-07 2011-01-06 Hedgehog inhibitors

Publications (2)

Publication Number Publication Date
AU2011204370A1 AU2011204370A1 (en) 2012-07-05
AU2011204370B2 true AU2011204370B2 (en) 2015-03-05

Family

ID=44305789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011204370A Ceased AU2011204370B2 (en) 2010-01-07 2011-01-06 Hedgehog inhibitors

Country Status (10)

Country Link
US (1) US9174949B2 (enExample)
EP (1) EP2521451A4 (enExample)
JP (1) JP2013516480A (enExample)
KR (1) KR20120099155A (enExample)
CN (1) CN102802419A (enExample)
AU (1) AU2011204370B2 (enExample)
CA (1) CA2785204C (enExample)
MX (1) MX2012007929A (enExample)
PH (1) PH12012501389A1 (enExample)
WO (1) WO2011085128A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
JP2013516480A (ja) 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． ヘッジホッグ阻害剤
WO2014043715A1 (en) * 2012-09-17 2014-03-20 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015031710A1 (en) * 2013-08-29 2015-03-05 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US10521327B2 (en) * 2016-09-29 2019-12-31 2236008 Ontario Inc. Non-coupled software lockstep
WO2019014315A1 (en) * 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. RAD51 INHIBITORS
WO2025232650A1 (zh) * 2024-05-07 2025-11-13 南京同诺康医药科技有限公司 Kif18a抑制剂及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030952A2 (en) * 2007-09-05 2009-03-12 Astrazeneca Ab Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009151495A2 (en) * 2008-03-18 2009-12-17 Amgen Inc. Oxazole compounds, compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362369B2 (en) * 1997-11-25 2002-03-26 Nihon Nohyaku Co., Ltd. Phthalic acid diamide derivatives fluorine-containing aniline compounds as starting material, agricultural and horticultural insecticides, and a method for application of the insecticides
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
EP1725544B1 (en) 2004-03-09 2009-05-27 Boehringer Ingelheim Pharmaceuticals Inc. 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
RU2007119637A (ru) 2004-10-28 2008-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов hedgehog-пути
EP1957461B1 (en) 2005-11-14 2016-11-02 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
WO2009146013A1 (en) * 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
WO2010127152A2 (en) 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2011014888A1 (en) 2009-07-31 2011-02-03 Selexagen Therapeutics Novel hedgehog inhibitors
JP2013516480A (ja) 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． ヘッジホッグ阻害剤
WO2011085261A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030952A2 (en) * 2007-09-05 2009-03-12 Astrazeneca Ab Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009151495A2 (en) * 2008-03-18 2009-12-17 Amgen Inc. Oxazole compounds, compositions and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALDEA, I. et al. "Kinetics of the hydrolysis of N-benzoyl derivatives of 2-phenyl-4-(4'-aminophenyl)thiazole, 4-aminobiphenyl, and some related compounds" Studia Universitatis Babes-Bolyai Chemia 1981, 26(2), 62-6 *
CA accession no. 97:71688 *
CHEMICAL ABSTRACTS, DATABASE REGISTRY: Compound with Registry Number 1036693-42-1, Entered STN: 28 July 2008. *
CHEMICAL ABSTRACTS, DATABASE REGISTRY: Compound with Registry Number 1100176-98-4, Entered STN: 03 February 2009. *
CHEMICAL ABSTRACTS, DATABASE REGISTRY: Compound with Registry Number 1100228-91-8, Entered STN: 03 February 2009. *

Also Published As

Publication number Publication date
AU2011204370A1 (en) 2012-07-05
US9174949B2 (en) 2015-11-03
EP2521451A1 (en) 2012-11-14
CA2785204C (en) 2016-01-05
WO2011085128A1 (en) 2011-07-14
KR20120099155A (ko) 2012-09-06
CA2785204A1 (en) 2011-07-14
US20130012513A1 (en) 2013-01-10
MX2012007929A (es) 2012-11-21
CN102802419A (zh) 2012-11-28
PH12012501389A1 (en) 2012-10-29
EP2521451A4 (en) 2013-08-21
JP2013516480A (ja) 2013-05-13

Similar Documents

Publication Publication Date Title
CA2785204C (en) Hedgehog inhibitors
RU2491286C1 (ru) Полиморфная форма соединения 2-аминотиазола в качестве ингибитора киназы и способ ее получения
KR102475498B1 (ko) 리신 특이적 데메틸라아제-1의 억제제
JP7741981B2 (ja) Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用
WO2011085261A1 (en) Hedgehog inhibitors
KR20240109267A (ko) 리신 아세틸트랜스퍼라제 6a (kat6a) 억제제 및 그의 용도
WO2015168466A1 (en) Inhibitors of lysine specific demethylase-1
WO2004113303A1 (en) INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF
CA2954060A1 (en) Inhibitors of lysine specific demethylase-1
CA2674389A1 (en) Rho kinase inhibitors
CA3202033A1 (en) Selective inhibitors of rock1 and rock2 protein kinases and uses thereof
WO2011014888A1 (en) Novel hedgehog inhibitors
HK1179113A (en) Hedgehog inhibitors
EP4727943A1 (en) Inhibitors of met kinase
US20230150946A1 (en) Heterocycle containing stat inhibitors and compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired